Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

Objective Secukinumab provided sustained efficacy, low radiographic progression and consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 study. Here, we report 2-year (end-of-study) results from this study.Methods Adults with active PsA were randomised 2:2:2:3 t...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Robert Landewé, Désirée van der Heijde, Philip J Mease, Hasan Tahir, Shephard Mpofu, Luminita Pricop, Proton Rahman, Atul Singhal, Sandra Navarra, Aimee Readie, Elke Boettcher, Eumorphia Maria Delicha
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMJ Publishing Group 2021-08-01
Reeks:	RMD Open
Online toegang:	https://rmdopen.bmj.com/content/7/2/e001600.full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!